Physician profile
Michael P Harris
NPI 1376551903
$4,060.56
in general payments reported to CMS, 2019-2025
44 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985 · 2020: $158 · 2021: $136 · 2022: $807 · 2023: $689 · 2024: $545 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $666.39 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $364.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $332.96 | 2019-2025 | |
| Dexcom, INC. | $247.65 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $212.07 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $203.68 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $203.23 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $185.58 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.35 | 2019-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $124.61 | 2022-2025 | Rexulti |
| Abbvie INC. | $109.19 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $107.94 | 2019-2023 | Spravato |
| Novartis Pharmaceuticals Corporation | $95.86 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.46 | 2019-2025 | Jardiance |
| Dynavax Technologies Corporation | $79.69 | 2023-2025 | Heplisav-B |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.